Skip to main content
eScholarship
Open Access Publications from the University of California

Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non-small-cell Lung Cancer.

  • Author(s): Al-Obeidi, Ebaa
  • Li, Tianhong
  • Kelly, Karen
  • et al.
Main Content
Current View